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Table. Femoral vein harvest cases: Indications and duplex follow-up
No. Age/gender Indication for femoral vein harvest Follow-up Duration of therapeutic anticoagulation Duplex/CEAP
1 79/M Femoral vs AV access 13 months 10 days No DVT/C0
2 78/M Femoral vs AV access 12 months 10 days No DVT/C0
3 67/M Portal vs repair 1 montha 30 days —
4 62/M Iliac graft infection 19 months 10 days Amputation
5 45/M Femoral vs AV access 21 months 10 days No DVT/C5
b
6 73/F Femoral vs AV access 18 months 30 days No DVT/C0
7 86/F Femoral vs AV access 3 daysc 3 days —
8 74/M Femoral vs AV access 7 months 30 days No DVT/C0
9 61/M Mycotic AAA repair 5 months Thromboprophylaxis only Stump DVT/C3
AAA, Abdominal aortic aneurysm; AV, arteriovenous; CEAP, clinical, etiology, anatomy, pathophysiology classiﬁcation; DVT, deep vein thrombosis;
F, female; M, male.
aDeath postoperative day 30.
bHealed ulcer from previous to femoral vein harvest suppurative superﬁcial thrombophlebitis.
cDeath postoperative day 3.
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for at least 10 days postoperatively.
Despite the fact that thrombosis in the retained venous stump
is of questionable clinical consequence, there is always concern of
a lag time of several years before the full extent of any venous
morbidity would be noted clinically. The possibility of thrombosis
distal to the vein harvest and any subsequent venous morbidity
should be minimized by proper therapeutic anticoagulation in
the immediate postoperative period, allowing time for optimal
venous collateral circulation remodeling.
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Reply
We greatly appreciate the opportunity to reply to this well-
formulated Letter to the Editor. Deep vein thrombosis (DVT) is
a frequent clinical sequela of the femoral vein harvest (FVH)
procedure. In our study, we observed a high rate of DVT after
FVH only in patients with cancer. Also, DVTs proximal to the
FVH segment were observed only in patients with cancer. Thus,
our recommendation for prophylactic low-molecular-weight
heparin in the postoperative period was for these patients with
cancer to prevent DVT proximal to the harvested femoral vein.The majority of DVTs occurring after FVH were diagnosed
in the retained popliteal vein stump, as correctly pointed out by
the authors in the Letter to the Editor. In our study, the incidence
of retained venous stump DVT was signiﬁcantly lower in patients
without cancer (10% vs 52%). We agree that limited information is
available about the clinical consequence of DVT in the popliteal
vein stump. The study by Wells et al,1 in which 16 limbs with
thrombus in the retained popliteal vein segment after FVH were
compared with 70 limbs without DVT, provides some insight.
Over a mean follow-up period of 3 years, they did not observe
any additional morbidity in limbs with popliteal DVT compared
with limbs without DVT. In that study, none of the patients
were treated for DVT in retained popliteal segment.1 Given
these limited data, we do not routinely treat DVT distal to the
FVH site.
It is always ideal to prevent a DVT, even one with questionable
clinical consequence. However, the optimal method for preventing
a popliteal DVT after FVH is uncertain. Therapeutic anticoagula-
tion is one option. However, in patients without cancer, most of
whom do not develop DVT in the distal vein segment, giving ther-
apeutic anticoagulation in the immediate postoperative period
would expose most of them to the risks of anticoagulation with
minimal beneﬁt. Moreover, the duration of therapeutic anticoagu-
lation to prevent popliteal DVT after FVH is somewhat arbitrary.
Based on our data, a signiﬁcant number of DVTs were diagnosed
more than 10 days after the procedure. Thus, administering thera-
peutic anticoagulation for the ﬁrst 10 days (as suggested by the
authors) may not prevent a signiﬁcant proportion of DVTs in the
retained popliteal vein stump. Given the low incidence of popliteal
DVT in patients without cancer, it is difﬁcult to justify therapeutic
anticoagulation in this population, especially when the clinical
consequence of DVT in the distal popliteal vein is minimal. It is
an interesting proposition to investigate the role of therapeutic anti-
coagulation in cancer patients who require an FVH procedure to
prevent DVT proximal to the harvest site.
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